In:
Cancer, Wiley, Vol. 123, No. 22 ( 2017-11-15), p. 4403-4410
Kurzfassung:
RE‐STIM is a French observational, multicenter study evaluating treatment‐free remission in 70 patients who re‐attempt tyrosine kinase inhibitor discontinuation after a first unsuccessful attempt, with the loss of a major molecular response used as a trigger for therapy re‐introduction. No safety issue is reported, and the treatment‐free remission rate at 36 months is 34% (95% confidence interval, 23.6%‐49%), demonstrating that a first failed attempt at discontinuing tyrosine kinase inhibitor does not preclude a second successful attempt.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v123.22
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1